Clinical trial
The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
NCT02793128 · UroGen Pharma Ltd., Industry · Completed
Key facts
| NCT number | NCT02793128 |
|---|---|
| Title | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study |
| Official title | A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma |
| Acronym | Olympus |
| Lead sponsor | UroGen Pharma Ltd., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis |
| Intervention type | Drug |
| Interventions | UGN-101 instillations |
| Enrollment | 71 |
| Start date | Apr 4, 2017 |
| Primary completion | Apr 5, 2019 |
| Completion | Mar 5, 2020 |
| First posted | Jun 8, 2016 |
| Last update posted | Dec 22, 2020 |
| Countries | Israel, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: